Edap TMS SA (EDAP)
2.47
-0.02
(-0.80%)
USD |
NASDAQ |
Nov 22, 16:00
2.47
0.00 (0.00%)
After-Hours: 20:00
Edap TMS Cash from Investing (Quarterly): -1.120M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -1.120M |
| June 30, 2024 | -0.8037M |
| March 31, 2024 | -1.193M |
| December 31, 2023 | -0.8921M |
| September 30, 2023 | -0.9178M |
| June 30, 2023 | -1.617M |
| March 31, 2023 | -1.276M |
| December 31, 2022 | 17.38M |
| Date | Value |
|---|---|
| September 30, 2022 | -18.61M |
| June 30, 2022 | -0.4932M |
| March 31, 2022 | -0.7765M |
| December 31, 2021 | -0.7731M |
| September 30, 2021 | -0.3888M |
| June 30, 2021 | -0.4219M |
| March 31, 2021 | -0.3543M |
| March 31, 2020 | -2.219M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-18.61M
Minimum
Sep 2022
17.38M
Maximum
Dec 2022
-0.9052M
Average
-0.8479M
Median
Cash from Investing (Quarterly) Benchmarks
| DBV Technologies SA | -0.109M |
| Cellectis SA | 22.33M |
| Genfit SA | -- |
| Adaptimmune Therapeutics PLC | -66.02M |
| Akari Therapeutics PLC | -- |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -5.573M |
| Cash from Financing (Quarterly) | 0.6422M |
| Free Cash Flow | -24.95M |
| Free Cash Flow Per Share (Quarterly) | -0.1797 |
| Free Cash Flow to Equity (Quarterly) | -7.677M |
| Free Cash Flow to Firm (Quarterly) | -6.693M |
| Free Cash Flow Yield | -27.21% |